Intrathecal baclofen therapy for management of spasticity: An Australian paediatric multicentre prospective audit.

Not Applicable

• Conditions: Cerebral Palsy; Spinal Cord Injury; Neurological - Other neurological disorders

• Registration Number: ACTRN12610000323022
• Lead Sponsor: Princess Margaret Hospital for Children

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Enrolment in this paediatric long term outcome audit will be offered to new patients offered ITB therapy.

The decision whom is offered ITB therapy in Western Australia rests with Movement Disorder’s team at Princess Margaret Hospital. This decision is made following a multidisciplinary medical assessment process including a test dose of intrathecal baclofen.

Hospitals providing paediatric ITB programmes in Australia include Princess Margaret Hospital for Children (Perth), Royal Childrens Hospital (Melbourne), Monash Medical Centre (Melbourne), Westmead Childrens Hospital (Sydney), Women & Childrens Hospital (Adelaide) and the Royal Childrens Hospital (Brisbane).

Exclusion Criteria

There are no specific exclusion criteria.

Study & Design

• Study Type: Observational
• Study Design: Not specified